<description>&lt;div data-contents="true"&gt; &lt;div class="" data-block="true" data-editor="50d09" data-offset-key="a8bfq-0-0"&gt; &lt;ol&gt; &lt;li&gt;&lt;span data-offset-key="a8bfq-0-0"&gt;Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer | NEJM&lt;/span&gt; &lt;span style="color: #1d9bf0;"&gt;&lt;span data-offset-key= "a8bfq-1-0"&gt;https://www.nejm.org/doi/full/10.1056/NEJMoa2203690#.YsoGdaAS_fY.twitter&lt;/span&gt;&lt;/span&gt;&lt;/li&gt; &lt;li data-block="true" data-editor="e0r4j" data-offset-key= "ak2kq-0-0"&gt; &lt;div class= "public-DraftStyleDefault-block public-DraftStyleDefault-ltr" data-offset-key="ak2kq-0-0"&gt;&lt;span data-offset-key= "ak2kq-0-0"&gt;DESTINY-Changing Results for Advanced Breast Cancer | NEJM&lt;/span&gt; &lt;span style="color: #1d9bf0;"&gt;&lt;span data-offset-key= "ak2kq-1-0"&gt;&lt;a href= "https://www.nejm.org/doi/full/10.1056/NEJMe2206661#.YsoGjty1ahE.twitter"&gt; https://www.nejm.org/doi/full/10.1056/NEJMe2206661#.YsoGjty1ahE.twitter&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;div class= "public-DraftStyleDefault-block public-DraftStyleDefault-ltr" data-offset-key="ak2kq-0-0"&gt; &lt;/div&gt; &lt;/li&gt; &lt;li data-block="true" data-editor="e0r4j" data-offset-key= "ak2kq-0-0"&gt; &lt;div class= "public-DraftStyleDefault-block public-DraftStyleDefault-ltr" data-offset-key="ak2kq-0-0"&gt;&lt;span data-offset-key="flnbj-0-0"&gt;Early Detection and Monitoring of Vulnerable Myocardium in Patients Receiving Chemotherapy: Is It Time to Change Tracks?&lt;/span&gt; &lt;span style="color: #1d9bf0;"&gt;&lt;span data-offset-key= "flnbj-1-0"&gt;https://www.heartfailure.theclinics.com/article/S1551-7136(11)00037-7/fulltext#.YsoHTLcs3-M.twitter&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/li&gt; &lt;li data-block="true" data-editor="e0r4j" data-offset-key= "ak2kq-0-0"&gt; &lt;div class= "public-DraftStyleDefault-block public-DraftStyleDefault-ltr" data-offset-key="ak2kq-0-0"&gt;&lt;span style="color: #000000;"&gt;Using a Magnet to Strike Gold&lt;/span&gt;&lt;/div&gt; &lt;div class= "public-DraftStyleDefault-block public-DraftStyleDefault-ltr" data-offset-key="ak2kq-0-0"&gt;&lt;span style= "color: #1d9bf0;"&gt;&lt;span data-offset-key= "82h4r-1-0"&gt;https://www.heartfailure.theclinics.com/article/S1551-7136(09)00026-9/fulltext#.YsoG3Cq5rAs.twitter&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/li&gt; &lt;/ol&gt; &lt;/div&gt; &lt;/div&gt;</description>

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

Dr RR Baliga, MD, MBA

Food for Thought: Should the FDA, EMA, NCI, NHLBI, ICOS, ACC, AHA, mandate Cardio-Oncologists on Cancer Clinical Trials with Cardiotoxic Drugs?| Trastuzumab Cardiotoxicity in DESTINY-Breast04 Trial

APR 24, 20248 MIN
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

Food for Thought: Should the FDA, EMA, NCI, NHLBI, ICOS, ACC, AHA, mandate Cardio-Oncologists on Cancer Clinical Trials with Cardiotoxic Drugs?| Trastuzumab Cardiotoxicity in DESTINY-Breast04 Trial

APR 24, 20248 MIN

Description

  1. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2203690#.YsoGdaAS_fY.twitter
  2. DESTINY-Changing Results for Advanced Breast Cancer | NEJM https://www.nejm.org/doi/full/10.1056/NEJMe2206661#.YsoGjty1ahE.twitter  
  3. Early Detection and Monitoring of Vulnerable Myocardium in Patients Receiving Chemotherapy: Is It Time to Change Tracks? https://www.heartfailure.theclinics.com/article/S1551-7136(11)00037-7/fulltext#.YsoHTLcs3-M.twitter
  4. Using a Magnet to Strike Gold https://www.heartfailure.theclinics.com/article/S1551-7136(09)00026-9/fulltext#.YsoG3Cq5rAs.twitter